MX370795B - Una composición farmacéutica que contiene ácido nicotínico y/o nicotinamida y/o triptófano para influir positivamente en la microbiota intenstinal. - Google Patents

Una composición farmacéutica que contiene ácido nicotínico y/o nicotinamida y/o triptófano para influir positivamente en la microbiota intenstinal.

Info

Publication number
MX370795B
MX370795B MX2014015217A MX2014015217A MX370795B MX 370795 B MX370795 B MX 370795B MX 2014015217 A MX2014015217 A MX 2014015217A MX 2014015217 A MX2014015217 A MX 2014015217A MX 370795 B MX370795 B MX 370795B
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
tryptophan
nicotinic acid
nicotinamide
intestinal microbiota
Prior art date
Application number
MX2014015217A
Other languages
English (en)
Other versions
MX2014015217A (es
Inventor
Georg Waetzig
Dirk Seegert
Original Assignee
Conaris Res Institute Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conaris Res Institute Ag filed Critical Conaris Res Institute Ag
Publication of MX2014015217A publication Critical patent/MX2014015217A/es
Publication of MX370795B publication Critical patent/MX370795B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una nueva composición farmacéutica que contiene ácido nicotínico, nicotinamina, compuestos relacionados con triptófano para influir de manera positiva en la microbiota intestinal. En ciertas modalidades, la composición farmacéutica es liberada parcial o completamente en el intestino delgado o el intestino grueso. La figura más representativa de la invención es la número 1.
MX2014015217A 2012-06-15 2013-06-14 Una composición farmacéutica que contiene ácido nicotínico y/o nicotinamida y/o triptófano para influir positivamente en la microbiota intenstinal. MX370795B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102012011890 2012-06-15
PCT/EP2013/062363 WO2013186355A1 (en) 2012-06-15 2013-06-14 A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota

Publications (2)

Publication Number Publication Date
MX2014015217A MX2014015217A (es) 2015-03-05
MX370795B true MX370795B (es) 2020-01-08

Family

ID=47002494

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014015217A MX370795B (es) 2012-06-15 2013-06-14 Una composición farmacéutica que contiene ácido nicotínico y/o nicotinamida y/o triptófano para influir positivamente en la microbiota intenstinal.

Country Status (32)

Country Link
US (2) US10426765B2 (es)
EP (2) EP2861229B1 (es)
JP (3) JP6855165B2 (es)
KR (2) KR102211832B1 (es)
CN (2) CN108273064A (es)
AR (1) AR091465A1 (es)
AU (1) AU2013276451B2 (es)
BR (1) BR112014030835B1 (es)
CA (1) CA2876540C (es)
CY (1) CY1123999T1 (es)
DK (1) DK2861229T3 (es)
ES (1) ES2859758T3 (es)
HR (1) HRP20210090T1 (es)
HU (1) HUE053359T2 (es)
IL (1) IL236205B (es)
IN (1) IN2014DN10260A (es)
JO (1) JO3578B1 (es)
LT (1) LT2861229T (es)
MX (1) MX370795B (es)
NZ (1) NZ702297A (es)
PH (1) PH12014502744A1 (es)
PL (1) PL2861229T3 (es)
PT (1) PT2861229T (es)
RS (1) RS61288B1 (es)
RU (1) RU2657797C2 (es)
SA (1) SA113340643B1 (es)
SG (1) SG11201408251SA (es)
SI (1) SI2861229T1 (es)
SM (1) SMT202100248T1 (es)
TW (1) TWI624260B (es)
WO (1) WO2013186355A1 (es)
ZA (1) ZA201408922B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2876540C (en) 2012-06-15 2022-11-29 Conaris Research Institute Ag A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
PL3003298T3 (pl) * 2013-06-05 2024-07-15 The University Of British Columbia Związki antyfibrogenne, sposoby ich zastosowania
US10456389B2 (en) * 2013-06-14 2019-10-29 Conaris Research Institute Ag Extended release nicotinamide formulation
JP6895752B2 (ja) 2013-12-13 2021-06-30 コナリス リサーチ インスティチュート アーゲー ニコチン酸および／またはニコチンアミドを含む、腸内微生物叢を改変することにより血中脂質レベルに有益に影響を及ぼすための医薬組成物
EP2884282A1 (en) 2013-12-13 2015-06-17 CONARIS research institute AG Use of tryptophan as a biomarker for patient selection, dosing and therapy monitoring for pharmaceutical compositions targeting the intestinal microbiota in diseases featuring tryptophan deficiency
ES2716115T3 (es) 2013-12-13 2019-06-10 Conaris Res Institute Ag Una composición farmacéutica que contiene conbinaciones de nicotinamida y ácido 5-aminosalicílico para influir de forma beneficiosa en la microbiota intestinal y/o tratar la inflamación gastrointestinal
WO2015124637A1 (en) * 2014-02-18 2015-08-27 Conaris Research Institute Ag Methods and compositions for intestinal microenvironment transfer
CN106413680A (zh) * 2014-05-12 2017-02-15 荷兰联合利华有限公司 用于诱导抗微生物肽生成的烟酰胺
CN105287561A (zh) * 2015-11-25 2016-02-03 上海交通大学医学院附属瑞金医院 一种治疗溃疡性结肠炎的药物组合物
CA3021022C (en) * 2016-04-14 2024-04-23 ChromaDex Inc. Use of nicotinamide riboside, nicotinic acid riboside, nicotinamide mononucleotide, and nicotinoyl compound derivatives in infant formula
ES2848575T3 (es) * 2016-04-19 2021-08-10 Conaris Res Institute Ag Composiciones farmacéuticas orales de nicotinamida
CN109310642B (zh) 2016-04-19 2021-07-20 费灵有限公司 美沙拉嗪的口服药物组合物
CN109718234A (zh) * 2017-10-31 2019-05-07 中国农业大学 L-色氨酸在缓解肠道炎症反应和屏障功能紊乱中的应用
CN108935981B (zh) * 2018-06-05 2026-05-05 西北农林科技大学 围产期奶山羊添加烟酰胺对羔羊糖脂代谢的影响及其机制
EP3925450A4 (en) * 2019-02-12 2022-09-21 Megumi Tanaka FOOD OR DRINK FOR BABIES AND INFANTS, METHODS OF IMPROVING THE INTESTINAL ENVIRONMENT OF A BABY OR INFANTS, AND METHODS OF BOOSTING THE IMMUNITY OF A BABY OR INFANTS
US12357612B2 (en) 2019-03-28 2025-07-15 Tohoku University Prophylactic or therapeutic agent for cancer
CN113398130A (zh) * 2020-03-16 2021-09-17 广州市妇女儿童医疗中心（广州市妇幼保健院、广州市儿童医院、广州市妇婴医院、广州市妇幼保健计划生育服务中心） 烟酰胺用于预防和治疗胃肠道功能紊乱的用途
JP2023550994A (ja) * 2020-11-27 2023-12-06 コナリス リサーチ インスティテュート アクチェンゲゼルシャフト Ｃｏｖｉｄ－１９及びその他のウイルス感染症の患者の症状の消散までの時間を低減するためのニコチンアミド、ニコチンアミド前駆体及びニコチンアミド代謝体並びにそれらの組成物
CN116635025A (zh) * 2020-11-27 2023-08-22 康纳里斯研究院股份公司 用于缩短covid-19和其他病毒感染患者的症状消退时间的烟酰胺、烟酰胺前体和烟酰胺代谢物及其组合物
JPWO2023002939A1 (es) * 2021-07-19 2023-01-26
EP4499059A1 (en) * 2022-03-30 2025-02-05 CONARIS research institute AG Composition comprising nicotinamide, nicotinamide precursors, nicotinamide metabolites or combinations thereof for preventing or reducing one or more post-acute symptoms of infectious diseases
KR102789810B1 (ko) 2023-02-06 2025-03-31 한림대학교 산학협력단 아토피 피부염 진단용 바이오마커
CN117837697A (zh) * 2023-12-22 2024-04-09 汕头大学 一种烟酰胺的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
DE19524928A1 (de) * 1995-07-08 1997-01-09 Basf Ag Verfahren zur Rektifikation von Gemischen hochsiedender luft- und/oder temperaturempfindlicher Substanzen, die eine hohe Trennleistung erfordern, im Feinvakuum, sowie für dieses Verfahren geeignete Kolonnen
US5846983A (en) * 1996-02-09 1998-12-08 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
US5736532A (en) * 1996-02-14 1998-04-07 Furda; Ivan Multifunctional fat absorption and blood cholesterol reducing formulation comprising chitosan
GB9614902D0 (en) * 1996-07-16 1996-09-04 Rhodes John Sustained release composition
KR20010102963A (ko) * 1998-12-23 2001-11-17 윌리암스 로저 에이 심장 혈관 징후를 위한 회장 담즙산 수송 저해제와니코틴산 유도체의 조합물
US6713057B1 (en) 1999-02-24 2004-03-30 The Johns Hopkins University Compositions and methods for modulating serum cholesterol
GB0015242D0 (en) 2000-06-22 2000-08-16 Nycomed Amersham Plc Stabiliser for radiopharmaceuticals
WO2002011725A1 (en) 2000-08-08 2002-02-14 Shionogi & Co., Ltd. Inflammatory cytokine production inhibitors
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
US7417037B2 (en) 2004-01-20 2008-08-26 The Board Of Regents Of The University Of Oklahoma Compositions and methods of treatment for inflammatory diseases
US20060264409A1 (en) 2004-01-20 2006-11-23 Harty Richard F Compositions and methods of treatment for inflammatory diseases
WO2005115075A2 (en) 2004-05-27 2005-12-08 Antibe Therapeutics Inc. Salt of 4- or 5- aminosalicylic acid
CA2581816A1 (en) * 2004-09-27 2006-04-06 Sigmoid Biotechnologies Limited Microcapsules comprising a methylxanthine and a corticosteroid
JPWO2007004613A1 (ja) * 2005-07-01 2009-01-29 味の素株式会社 炎症性腸疾患治療薬及びＴＮＦ−α産生抑制剤
DK2026651T3 (da) * 2006-03-08 2013-07-08 Cortria Corp Kombinationsterapi med ikke-selektive COX-inhibitorer til forebyggelse af COX-relaterede maveskader
ITMI20061932A1 (it) 2006-10-09 2008-04-10 Carlo Ghisalberti Complessi a trasferimento di carica per uso medicale
EP1935422A1 (en) * 2006-12-20 2008-06-25 PEJO Iserlohn Heilmittel-und Diät-GmbH & Co.KG Pharmaceutical composition comprising nicotinamide or nicotinic acid
US20090104171A1 (en) * 2007-10-19 2009-04-23 Pardee Joel D Metabolic Enhancement Therapy
EP2276491A4 (en) * 2008-04-25 2011-08-17 Karolinska Inst Innovations Ab NEW THERAPY FOR THE TREATMENT OF IRRITATION SYNDROME
AU2009249600A1 (en) * 2008-05-20 2009-11-26 Cerenis Therapeutics Holding S.A. Niacin and NSAID for combination therapy
MX2010013169A (es) 2008-06-02 2010-12-21 Reddy S Lab Ltd Formulaciones de niacina de liberacion modificada.
WO2010040113A1 (en) 2008-10-03 2010-04-08 Salix Pharmaceuticals, Ltd. Compositions and methods for the treatment of bowel diseases with granulated mesalamine
JP2011121889A (ja) 2009-12-09 2011-06-23 En Otsuka Pharmaceutical Co Ltd 炎症性腸疾患用アミノ酸組成物
JP2012102054A (ja) 2010-11-11 2012-05-31 Kyodo Milk Industry Co Ltd 腸内ポリアミン増強剤
WO2012090224A1 (en) 2010-12-29 2012-07-05 Nutracryst Therapeutics Private Limited Novel cocrystals / molecular salts of mesalamine to be used as improved anti-inflammatory drug
CA2876540C (en) 2012-06-15 2022-11-29 Conaris Research Institute Ag A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
US10456389B2 (en) 2013-06-14 2019-10-29 Conaris Research Institute Ag Extended release nicotinamide formulation
ES2848575T3 (es) 2016-04-19 2021-08-10 Conaris Res Institute Ag Composiciones farmacéuticas orales de nicotinamida
JP2023550994A (ja) * 2020-11-27 2023-12-06 コナリス リサーチ インスティテュート アクチェンゲゼルシャフト Ｃｏｖｉｄ－１９及びその他のウイルス感染症の患者の症状の消散までの時間を低減するためのニコチンアミド、ニコチンアミド前駆体及びニコチンアミド代謝体並びにそれらの組成物

Also Published As

Publication number Publication date
NZ702297A (en) 2016-11-25
ES2859758T3 (es) 2021-10-04
SI2861229T1 (sl) 2021-03-31
IN2014DN10260A (es) 2015-08-07
HRP20210090T1 (hr) 2021-03-05
MX2014015217A (es) 2015-03-05
IL236205B (en) 2020-02-27
US10426765B2 (en) 2019-10-01
CN108273064A (zh) 2018-07-13
EP2861229A1 (en) 2015-04-22
DK2861229T3 (da) 2021-01-18
PT2861229T (pt) 2021-01-05
SA113340643B1 (ar) 2019-10-06
JO3578B1 (ar) 2020-07-05
KR20150021071A (ko) 2015-02-27
JP6855165B2 (ja) 2021-04-07
WO2013186355A1 (en) 2013-12-19
PL2861229T3 (pl) 2021-08-09
RU2014148239A (ru) 2016-08-10
EP3831379B1 (en) 2025-09-10
CN104363907A (zh) 2015-02-18
TWI624260B (zh) 2018-05-21
JP2022017332A (ja) 2022-01-25
CA2876540A1 (en) 2013-12-19
AR091465A1 (es) 2015-02-04
RU2657797C2 (ru) 2018-06-15
SG11201408251SA (en) 2015-01-29
BR112014030835A2 (pt) 2017-06-27
AU2013276451B2 (en) 2018-03-29
US20200009124A1 (en) 2020-01-09
LT2861229T (lt) 2021-01-25
IL236205A0 (en) 2015-01-29
JP2019069972A (ja) 2019-05-09
ZA201408922B (en) 2016-10-26
KR20200011619A (ko) 2020-02-03
HK1204972A1 (en) 2015-12-11
HUE053359T2 (hu) 2021-06-28
CY1123999T1 (el) 2022-05-27
BR112014030835B1 (pt) 2022-01-11
KR102211832B1 (ko) 2021-02-02
US20150126462A1 (en) 2015-05-07
EP2861229B1 (en) 2020-12-23
CA2876540C (en) 2022-11-29
EP3831379A1 (en) 2021-06-09
AU2013276451A1 (en) 2015-01-15
TW201400116A (zh) 2014-01-01
RS61288B1 (sr) 2021-02-26
SMT202100248T1 (it) 2021-05-07
JP2015519388A (ja) 2015-07-09
PH12014502744A1 (en) 2015-02-02

Similar Documents

Publication Publication Date Title
MX2014015217A (es) Una composicion farmaceutica que contiene acido nicotinico y/o nicotinamida y/o triptofano para influir positivamente en la microbiota intenstinal.
BR112015022545A2 (pt) compostos de pirazolo e os usos disso
BR112015000106A2 (pt) moduladores heterocíclicos de síntes de lipídio
MX338515B (es) Derivados de tetrahidroquinolina utiles como inhibidores de bromodominio.
EP2832851A4 (en) IMMORTALIZED STEM CELLS AND MEDICAL COMPOSITION AND MEDICAMENT WITH A PRODUCT THEREOF AS AN ACTIVE SUBSTANCE
UA110054C2 (uk) Розгалужені похідні 3-фенілпропіонової кислоти і їх застосування
MX2016003486A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
UY33370A (es) Composiciones farmacéuticas comprendiendo un fármaco inhibidor de la DPP4 y de la pioglitazona, procedimientos de preparación y utilización
MX2019006878A (es) Uso de flecainida como un agente anti-conexina y metodo para potenciar los efectos de un farmaco psicotropico.
HUE050146T2 (hu) Mikroorganizmust tartalmazó készítmény alkalmazása a vajsav, folsav vagy niacin béltermelés fokozására és/vagy a borostyánkõsav béltermelés csökkentésére
GT201500053A (es) Composicion farmaceutica recubierta que contiene regorafenib
WO2015086843A3 (en) A pharmaceutical composition containing nicotinic acid and/or nicotinamide for beneficially influencing blood lipid levels by modifying the intestinal microbiota
EA201201658A1 (ru) Производные пиперидина и их применение для лечения метаболических нарушений
MX360554B (es) Composiciones que comprenden y metodos que utilizan inhibidores de co-transportadores de glucosa-sodio 1 y 2.
PE20142043A1 (es) Enfoque metabolico selectivo para aumentar la biodisponibilidad oral de la fenilefrina y otros bioactivos metabolicos
BR112015017251A2 (pt) composições farmacêuticas compreendendo doadores de nitroxil
BR112012020989A2 (pt) composições veterinárias
GEP201706621B (en) Benzamides
MX340147B (es) Composiciones farmacéuticas y nutracéuticas del ácido abscísico.
CL2016001094A1 (es) Silicato de zirconio microporoso para el tratamiento de hipercalemia.
AR091495A1 (es) Sal de tipo camsilato
PH12016501059A1 (en) A pharmaceutical composition containing combinations of nicotinamide and 5-aminosalicylic acid for beneficially influencing the intestinal microbiota and/or treating gastrointestinal inflammation
BR112014020113A8 (pt) Composições farmacêuticas e método para diminuir a frequência de micção
CU24163B1 (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
AR090073A1 (es) N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos

Legal Events

Date Code Title Description
FG Grant or registration